Skip to main content

Table 1 Identified and validated fusion gene candidates

From: Identification of fusion genes in breast cancer by paired-end RNA-sequencing

Sample

5' gene

5' chromosome

3' gene

3' chromosome

Number of paired-end reads

Number of junction reads

In frame

Amplified

Genetic rearrangement validated

BT-474

ACACA

17

STAC2

17

57

72

Yes

Yes

Yes

BT-474

RPS6KB1

17

SNF8

17

43

68

Yes

Yes

Yes

BT-474

VAPB

20

IKZF3

17

41

26

Yes

Yes

Yes

BT-474

ZMYND8

20

CEP250

20

35

14

No

Yes

Yes

BT-474

RAB22A

20

MYO9B

19

9

12

No

Yes

Yes

BT-474

SKA2

17

MYO19

17

8

7

Yes

Yes

Yes

BT-474

DIDO1

20

KIAA0406

20

8

1

Yes

No

 

BT-474

STARD3

17

DOK5

20

4

6

Yes

Yes

Yes

BT-474

LAMP1

13

MCF2L

13

5

3

No

No

Yes

BT-474

GLB1

3

CMTM7

3

6

2

Yes

No

Yes

BT-474

CPNE1

20

PI3

20

4

2

No

Yes

Yes

SK-BR-3

TATDN1

8

GSDMB

17

28

447

Yes

Yes

Yes

SK-BR-3

CSE1L

20

ENSG00000236127

20

10

20

Yes

Yes

 

SK-BR-3

RARA

17

PKIA

8

13

10

Yes

Yes

Yes

SK-BR-3

ANKHD1

5

PCDH1

5

12

6

Yes

No

Yes

SK-BR-3

CCDC85C

14

SETD3

14

6

6

Yes

No

Yes

SK-BR-3

SUMF1

3

LRRFIP2

3

14

5

Yes

No

 

SK-BR-3

WDR67

8

ZNF704

8

3

3

Yes

Yes

Yes

SK-BR-3

CYTH1

17

EIF3H

8

38

2

Yes

Yes

Yes

SK-BR-3

DHX35

20

ITCH

20

3

2

Yes

No

Yes

SK-BR-3

NFS1

20

PREX1

20

5

9

Yes

Yes

 

KPL-4

BSG

19

NFIX

19

22

14

Yes

No

Yes

KPL-4

PPP1R12A

12

SEPT10

2

2

6

Yes

No

Yes

KPL-4

NOTCH1

9

NUP214

9

4

6

Yes

No

Yes

MCF-7

BCAS4

20

BCAS3

17

133

142

Yes

Yes

Previously reported

MCF-7

ARFGEF2

20

SULF2

20

17

25

Yes

Yes

Previously reported

MCF-7

RPS6KB1

17

TMEM49

17

2

7

Yes

Yes

Previously reported

  1. A total of 24 novel fusion genes were identified in BT-474, SK-BR-3 and KPL-4. Three fusion genes detected in MCF-7 have been reported before and served as positive controls in our study. Two paired-end reads and two fusion junction spanning short reads were required for selecting a fusion candidate for further validation. In-frame prediction, copy number amplification (at least one of the fusion partner genes) and validation of the genomic rearrangement are indicated. Lower level copy number gains were excluded.